

Merus

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

March 4, 2024 at 8:00 AM EST

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclronics[®] and Triclronics[®]), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 12:00 p.m. ET.

The webcast of the presentation will be contemporaneously available on the [investors page](#) of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus

[Merus](#) is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclronics[®]](#). Multiclronics[®] are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), [X](#) and [LinkedIn](#).

Multiclronics[®], Biclronics[®] and Triclronics[®] are registered trademarks of Merus N.V.

Investor and Media Inquiries:

Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl

Merus